ArticleAnnals of hematology2025

Cost-utility analysis of ropeginterferon alfa-2b to manage low-risk patients with polycythemia vera as compared to phlebotomy only in the Austrian healthcare system.

Evelyn Walter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.